Portfolio company Confo Therapeutics announced encouraging preclinical data for its post-bariatric hypoglycemia candidate CFTX-2034 at ENDO 2026.
JUN 15, 2026
Confo Therapeutics is a clinical-stage biotech company focused on accelerating novel medicines for metabolic and endocrine diseases using its proprietary GPCR-targeting technology
Confo Therapeutics is a clinical-stage biotech company focused on accelerating novel medicines for metabolic and endocrine diseases using its proprietary GPCR-targeting technology.